In This Article:
-
Revenue: $339 million for the first nine months of 2024, nearly nine times increase from the same period in 2023.
-
Product Revenue: $128 million for the first nine months, a 330% increase from the prior year.
-
Milestone Revenue: $211 million for the first nine months, compared to $8 million in the prior year.
-
Third Quarter Revenue: $103 million, up from $18 million in the prior year.
-
Third Quarter Product Revenue: $62 million, the highest recorded quarter by Alvotech, a 16% increase from Q2.
-
Product Margin: 37% in Q3, up from 17% in Q2.
-
Operating Profit: $56 million for the first nine months, compared to negative $278 million in the same period of 2023.
-
Adjusted EBITDA: $87 million for the first nine months, compared to negative $226 million in the prior year.
-
Cash on Hand: $118 million as of September 30, 2024.
-
Borrowings: $1.28 billion as of September 30, 2024.
-
Shares Outstanding: 301.7 million, including unvested earnout shares.
-
Revenue Guidance: $400 million to $500 million for 2024.
-
Cash Interest Payments Forecast: $45 million to $50 million for 2024.
Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Alvotech (NASDAQ:ALVO) reported a nearly ninefold increase in revenues for the first nine months of 2024 compared to the same period in 2023.
-
Product revenues rose to $128 million, driven by increased product sales in the third quarter.
-
The company achieved a significant improvement in product gross margins, which more than doubled in the third quarter compared to the second quarter.
-
Alvotech (NASDAQ:ALVO) successfully completed an FDA inspection of its manufacturing site in Reykjavik, Iceland, with only two observations, which are easily addressable.
-
The company is on track to launch its Stelara biosimilar in the US market in 2025, with all indications approved.
Negative Points
-
There remains uncertainty in the timing of shipments, which could impact revenue recognition between the fourth quarter of 2024 and the first quarter of 2025.
-
The company has not yet provided specific guidance for 2025, leaving some uncertainty about future financial performance.
-
Alvotech (NASDAQ:ALVO) faces potential challenges in the US market due to existing formulation patents for its biosimilar products.
-
The FDA inspection, although successful, resulted in two observations, indicating areas for improvement in compliance.
-
There is a wide range of potential outcomes for product mix and profitability, which could affect financial results.